… risk of stroke/SE and bleeding than warfarin in Asian AF … (DOACs; rivaroxaban, apixaban,
edoxaban, and dabigatran) have … Any product that may be evaluated in this article or claim that …

… risk of stroke by two-thirds in patients with non-valvular atrial … with apixaban, dabigatran,
rivaroxaban or warfarin between … rivaroxaban patients both had higher risk of major bleeding …

… to apixaban and dabigatran requiring twice-daily dosing compared with edoxaban or rivaroxaban
… We recruited patients who were first diagnosed with non-valvular AF between January …

… patients in this NMA received low-dose dabigatran (110 mg), … apixaban, dabigatran, and
rivaroxaban were more effective than warfarin on reducing the risks of stroke and haemorrhage; …

… in the present study because the expenses of apixaban and … -dose dabigatran, and those
on low-dose rivaroxaban had a … safety of dabigatran versus warfarin for GI bleeding, distinct …

… 50% of sample sized taking a low dose of DOAC 4) no clear … with warfarin, dabigatran,
rivaroxaban, and apixaban were … a specific non-valvular AF with different patient characteristics …

… treatment with a study medication or rivaroxaban or apixaban (… Finally, to the extent possible
using claims data, we … More importantly, whether warfarin management in our study was …

… experience with warfarin treatment, low-dose rivaroxaban (10 … (17) indicated that low-dose
apixaban was associated with a … rivaroxaban without lowering the adverse effect of bleeding …

… We compared stroke, bleeding, and mortality rates on and off therapy for standard and
low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort. We …

… 15 mg od, dabigatran 110 or 150 od, apixaban 2.5 mg od, or rivaroxaban 10 mg (without
the … of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal …